Study on Gene Activity and Chemotherapy Response in Metastatic Breast Cancer

Introduction

A recent study conducted by Dutch researchers explored the potential connection between tumor gene activity and chemotherapy responsiveness in patients suffering from metastatic breast cancer. The complexity of metastatic breast cancer, characterized by cancerous cells spreading and mutating in other body parts, poses challenges in predicting which patients will benefit from specific chemotherapy treatments.

Research Overview

Published in BMC Cancer, the study aimed to analyze the relationship between gene activity in original tumors and chemotherapy responses in metastatic breast cancer patients. Researchers collected medical data from Dutch patients who received hormonal therapy, chemotherapy, or a combination of both. Chemotherapy regimens were categorized into anthracycline-containing, taxane-containing, or other types.

Response Classification

Responses to chemotherapy were categorized into four types: complete responses (total tumor disappearance), partial responses (some tumor shrinkage), stable disease (no significant change), and progressive disease (increased tumor size or number). Patients exhibiting complete or partial responses were considered responsive, while those with stable or progressive disease were labeled non-responsive.

Gene Analysis Methodology

When original tumor samples were available, the researchers conducted gene analysis. Tumors were classified based on their molecular characteristics, including basal, HER2-like, luminal A, or luminal B. Additionally, gene activity patterns were assessed to determine their likelihood of responding to chemotherapy.

Patient Characteristics

Among the 263 patients involved in the study, 118 had original tumor samples available for analysis. Out of these, 21 patients received hormonal therapy before chemotherapy, 39 underwent chemotherapy alone, 15 received hormonal therapy only, and 44 were treated with a combination of both therapies.

Chemotherapy Response Rates

The study found that 42% of patients responded to first-line chemotherapy, while 22% responded to second-line therapies. However, no significant associations were identified between chemotherapy responsiveness and the original tumor’s behavior or molecular characteristics.

Gene Activity Findings

The investigation revealed 14 genes with significant differences between responders and non-responders to first-line chemotherapy. Among these, three genes exhibited reduced activity, while 11 showed increased activity in responders. The predictive value of this 14-gene responder profile was subsequently tested. Of the 43 patients with the responder profile, 33 were responsive to chemotherapy, while 42 of 46 patients without the profile were non-responsive. For second-line therapies, 9 of 37 with the responder profile responded, compared to 22 of 27 without it. Furthermore, original tumors with the responder profile tended to produce metastases later than those lacking this profile.

Conclusions

This study marks the first instance of demonstrating a correlation between the gene expression profiles of primary tumors and their responses to chemotherapy in metastatic breast cancer. The findings suggest that the identified 14-gene profile may serve as a predictor for chemotherapy response. However, as the profile was developed and validated within the study population, further testing in diverse cohorts is necessary for confirmation. Although no associations were found between molecular classifications and broader chemotherapy categories, exploring the responder gene profile’s predictive capabilities for other chemotherapy regimens remains a promising avenue for future research.

Reference

Savci-Heijink, C.D. et al. (2017). Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer. BMC Cancer. DOI 10.1186/s12885-017-3691-9